Canaccord Genuity Assumes SNDL at Speculative Buy, Announces Price Target of $3.25
$SNDL
Medicinal Chemicals and Botanical Products
Health Care
Canaccord Genuity analyst Yewon Kang assumes SNDL (NASDAQ:SNDL) with a Speculative Buy rating and announces Price Target of $3.25.